

# Restoring Health, Transforming Lives Through Innovation



Variant is a clinical stage orphan drug company leveraging advanced proprietary technologies to develop best-in-class drugs for patients with rare diseases.

Our lead asset is Phase 2a ready VAR 200, 2-hydroxypropyl-beta-cyclodextrin (2HPβCD) for treatment of focal segmental glomerulosclerosis (FSGS). VAR 200 entraps and removes lipids that can cause injury to the kidneys and other organs.

## Corporate Highlights

- Established in 2014
- Focus: \$100b+ Orphan Drug Market
- Licensed 2HPβCD from L&F Research and University of Miami for Treatment of Kidney Diseases
- Leading Indications:
  - FSGS: Induce and maintain remission of proteinuria; reduce rate of nephropathy progression
  - Alport Syndrome (AS): Induce and maintain remission of proteinuria; reduce rate of nephropathy progression

## Management Team

### Stephen C. Glover

*Co-founder, CEO & Chairman*

### Nicholas Labella, Jr. MS, RPh

*Acting Chief Scientific Officer*

### Pablo A. Guzman, MD, FACC

*Acting Chief Medical Officer*

### Peter Wolfe

*Acting VP, Finance*

### Karen A. Cashmere

*Acting VP, Marketing*

### Melda Uzbil

*Acting VP, Corporate Development*

### Brian Piper, PMP

*Acting VP, Project Management*

## Board of Directors

### Stephen C. Glover

*Variant Co-founder, CEO, & Chairman*

### Jules A. Müsing

*Lead Director of the Board, Pharmaceutical Executive & Advisor*

### Robert (Rob) G. Finizio

*CEO, Co-founder & Director, TherapeuticsMD*

### Anthony J. Giovinazzo

*Former President & CEO, Sunovion CNS Development Canada ULC*

### Aaron Greenblatt, Pharm D

*CEO, G&W Laboratories*

### Eric I. Richman

*Former President & CEO, PharmAthene*

## Orphan Pipeline, With Potential for Additional Indications

Variant Pipeline						
Description	Pre-Clinical	IND Ready	Phase 1	Phase 2	Phase 3	NDA Filed
VAR 200: 2HPβCD for FSGS	→		→			
VAR 300: 2HPβCD for AS	→					


\*FDA agreement to progress directly to Phase 2a

# Restoring Health, Transforming Lives Through Innovation



## 2-Hydroxypropyl-Beta-Cyclodextrin (2HP $\beta$ CD)

2HP $\beta$ CD is comprised of seven sugar molecules bound together in a ring (cyclic oligosaccharide). The ring-shaped, three-dimensional structure has a hydrophobic cavity in its center, which is capable of entrapping and removing intracellular cholesterol and lipids demonstrated to cause kidney damage and impaired function in conditions such as FSGS and Alport Syndrome.



## 2HP $\beta$ CD: Potential to Fulfill Significant Unmet Needs in Orphan Kidney Diseases

### Focal Segmental Glomerulosclerosis (FSGS) Market

- Affects up to 80,000 people in U.S.
- 5,400 new cases annually
- No disease-specific treatments
- 35% of patients in renal failure in 10 years
- 1,000 kidney transplants for FSGS/Year
- Recurs in 30% – 40% of transplant patients

### 2HP $\beta$ CD Opportunity

- Provide a first-in-class, FSGS disease modifying treatment
- Delay FSGS disease progression
- Prevent end-stage renal disease
- Improve quality of life

### Alport Syndrome (AS) Market

- Affects up to 60,000 people in U.S.
- No disease-specific treatments
- 90% males, 12% females in renal failure by age 40; 30% females by age 60
- Most deaf by age 40

### HP $\beta$ CD Opportunity

- Provide a first-in-class, AS disease modifying treatment
- Delay AS disease progression
- Prevent end-stage renal disease
- Improve quality of life